Background
Patients, materials and methods
MILD | IM-HLH or IM-CAEBV |
P-value | |
---|---|---|---|
(n = 31) | (n = 7) | ||
Gender | >o.o5 | ||
male | 18(58.1%) | 3(42.9%) | |
female | 13(41.9%) | 4(57.1%) | |
Age | >o.o5 | ||
0–14 | 24(77.4%) | 5(71.4%) | |
>14 | 7(22.6%) | 2(28.6%) | |
Leukocyte count | >o.o5 | ||
4 × 109/L | 7(22.6%) | 2(28.6%) | |
4–10 × 109/L | 8(25.8%) | 1(14.3%) | |
≥10 × 109/L | 16(51.6%) | 4(57.1%) | |
Median(range) | 10.85(1.2–43.0) | 14.9(1.5–61.0) | |
ALT or AST | >o.o5 | ||
high | 27(87.1%) | 7(100%) | |
normal/low | 4(12.9%) | 0(0%) | |
coagulopathy | >o.o5 | ||
positive | 22(74.2%) | 6(85.7%) | |
negative | 9(25.8%) | 1(14.3%) | |
ferritin high | >o.o5 | ||
high | 24(77.4%) | 6(85.7%) | |
normal/low | 7(22.6%) | 1(14.3%) | |
Triglyceride | >0.05 | ||
high | 24(77.4%) | 6(85.7%) | |
normal/low | 7(22.6%) | 1(14.3%) | |
hepatosplenomegaly | >o.o5 | ||
yes | 22(71.0%) | 6(85.7%) | |
no | 9(29.0%) | 1(14.3%) | |
lymphoadenopathy | >o.o5 | ||
yes | 24(77.4%) | 5(71.4%) | |
no | 7(22.6%) | 2(28.6%) | |
Days after onset of disease | <o.o5 | ||
average time | 34.8d | 119.7d(4/7, 3 decreased) |
Results
Atypical Lymphocytes (>10%) | HA test | EBV-IgM | EBV PCR | FISH | |
---|---|---|---|---|---|
mild IM(n = 31) | 26/31(83.9%) | 21/31(67.7%) | 23/31(71.2%) | 27/31(87.1%) | 30/31(96.8%) |
IM-HLH or IM-CAEBV(n = 7) | 6/7 (85.7%) | 5/7(71.4%) | 6/7(85.7%) | 7/7(100%) | 7/7(100%) |
Total(%) | 32/38(84.2%)* | 26/38(68.4%)**
| 29/38(76.3%)*
| 34/38(89.5%) | 37/38(97.4%) |
Num | Clinical type | HA test | EBV-VCA IgM | RT-PCR (copies/ml) | FISH positivity (per 100 cells) | FISH fluorescent | |
---|---|---|---|---|---|---|---|
particles | outcome | ||||||
1 | mild | - | 1:10 | 3.65×103
| 61.5% | 8.52/+ | alive |
2 | mild | + | - | 7.05×103
| 3.0% | 0.62/- | alive |
3 | mild | + | 1:20 | 6.26×105
| 66.0% | 11.42/+ | alive |
4 | mild | - | 1:160 | 6.21×103
| 54.5% | 13.06/+ | alive |
5 | mild | + | 1:320 | 4.75×105
| 56.5% | 13.78/+ | alive |
6 | mild | - | - | 2.02×104
| 62.0% | 29.91/+ | alive |
7 | mild | + | - | 4.35×104
| 42.5% | 7.78/+ | alive |
8 | mild | + | 1:640 | 9.05×104
| 65.0% | 10.75/+ | alive |
9 | mild | - | 1:160 | 7.32×105
| 57.5% | 11.35/+ | alive |
10 | mild | + | 1:160 | 3.45×103
| 72.5% | 14.52/+ | alive |
11 | mild | + | 1:80 | 5.09×105
| 63.0% | 7.89/+ | alive |
12 | mild | - | 1:160 | 7.32×103
| 56.5% | 9.24/+ | alive |
13 | mild | + | - | 3.26×103
| 70.5% | 6.28/+ | alive |
14 | mild | - | 1:80 | 8.25×105
| 50.5% | 10.79/+ | alive |
15 | mild | + | - | 6.32×103
| 63.0% | 11.24/+ | alive |
16 | mild | - | - | 9.37×105
| 41.5% | 13.52/+ | alive |
17 | mild | + | 1:160 | 8.02×105
| 67.5% | 14.36/+ | alive |
18 | mild | + | 1:80 | 7.22×103
| 70.5% | 9.01/+ | alive |
19 | mild | + | - | 6.91×104
| 52.0% | 19.43/+ | alive |
20 | mild | - | 1:20 | 6.44×103
| 45.5% | 11.21/+ | alive |
21 | mild | + | 1:80 | 4.28×105
| 35.5% | 12.36/+ | alive |
22 | mild | + | 1:20 | 1.75×104
| 45.5% | 13.42/+ | alive |
23 | mild | - | - | 3.92×105
| 72.5% | 14.53/+ | alive |
24 | mild | + | 1:320 | 1.07×104
| 65.5% | 14.76/+ | alive |
25 | mild | - | 1:20 | <500 | 42.0% | 13.23/+ | alive |
26 | mild | + | 1:20 | <500 | 53.0% | 9.17/+ | alive |
27 | mild | + | 1:80 | 3.05×103
| 67.0% | 8.79/+ | alive |
28 | mild | + | - | 3.59×105
| 71.0% | 6.42/+ | alive |
29 | mild | - | 1:40 | <500 | 39.0% | 5.75 /+ | alive |
30 | mild | - | 1:20 | <500 | 25.0% | 12.31/+ | alive |
31 | mild | - | 1:320 | 2.63×104
| 51.5% | 14.53/+ | alive |
32 | severe/EBV-HLH | + | 1:160 | 3.75×103
| 97.5% | 32.82/+ | alive |
33 | severe/EBV-HLH | - | 1:320 | 4.5×107
| 100% | 36.66/+ | deceased |
34 | severe/EBV-HLH | + | 1:640 | 3.05×104
| 89.5% | 39.08/+ | deceased |
35 | severe/EBV-HLH | + | - | 5.05×104
| 91.0% | 51.03/+ | alive |
36 | severe/CAEBV | + | 1:40 | 8.92×106
| 83.5% | 53.44/+ | alive |
37 | severe/CAEBV | - | 1:320 | 8.26×107
| 100% | 55.34/+ | deceased |
38 | severe/CAEBV | + | 1:80 | 4.75×105
| 87.5% | 48.28/+ | alive |